Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Immunotherapy Integrated Research Center, Fred Hutchison Cancer Center, Seattle, WA, USA.
Nat Cancer. 2024 Aug;5(8):1145-1157. doi: 10.1038/s43018-024-00798-x. Epub 2024 Jul 26.
While the effector cells that mediate anti-tumor immunity have historically been attributed to αβ T cells and natural killer cells, γδ T cells are now being recognized as a complementary mechanism mediating tumor rejection. γδ T cells possess a host of functions ranging from antigen presentation to regulatory function and, importantly, have critical roles in eliciting anti-tumor responses where other immune effectors may be rendered ineffective. Recent discoveries have elucidated how these differing functions are mediated by γδ T cells with specific T cell receptors and spatial distribution. Their relative resistance to mechanisms of dysfunction like T cell exhaustion has spurred the development of therapeutic approaches exploiting γδ T cells, and an improved understanding of these cells should enable more effective immunotherapies.
虽然介导抗肿瘤免疫的效应细胞在历史上归因于αβ T 细胞和自然杀伤细胞，但γδ T 细胞现在被认为是介导肿瘤排斥的一种补充机制。γδ T 细胞具有一系列功能，从抗原呈递到调节功能，重要的是，在其他免疫效应物可能无效的情况下，γδ T 细胞在引发抗肿瘤反应方面发挥着关键作用。最近的发现阐明了特定 T 细胞受体和空间分布如何介导这些不同的功能。它们对 T 细胞耗竭等功能障碍机制的相对抗性促使人们开发利用γδ T 细胞的治疗方法，对这些细胞的更好理解应该能够实现更有效的免疫疗法。
